caa a22 4500 39759058X CHVBK 20180308164937.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.6.1155 doi (NATIONALLICENCE)oxford-10.1093/jac/37.6.1155 Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis [Elektronische Daten] [Murray L. Barclay, Evan J. Begg, Stephen T. Chambers, Peter E. Thornley, Philip K. Pattemore, Keith Grimwood] Aminoglycoside antibiotics have been shown to induce adaptive resistance in Pseudomonas aeruginosa in vitro and in a mouse model of infection, but adaptive resistance has not been described in human infections. Seven patients with cystic fibrosis were treated with inhaled tobramycin to determine whether adaptive resistance occurred in P. aeruginosa in their sputum. In three patients who had not recently taken antibiotics, 80 mg tobramycin was administered by nebuliser and resulting peak sputum tobramycin concentrations were 90-240 mg/L (elimination half-life 1.9-2.1 h). Adaptive resistance was detected in P. aeruginosa 1-4 h after the dose of tobramycin. Moderate resistance was present at 24 h and full susceptibility returned between 24 and 48 h. In four other patients on long-term twice-daily inhaled aminoglycoside treatment, adaptive resistance was present before, and 4 h after, 80 mg of tobramycin administered by nebuliser. The presence and time course of adaptive resistance in humans may have implications for improving aminoglycoside dosing regimens. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence Barclay Murray L. Department of Clinical Pharmacology, Christchurch Hospital Christchurch, New Zealand aut Begg Evan J. Department of Clinical Pharmacology, Christchurch Hospital Christchurch, New Zealand aut Chambers Stephen T. Department of Infectious Diseases, Christchurch Hospital Christchurch, New Zealand aut Thornley Peter E. Department of Respiratory, Christchurch Hospital Christchurch, New Zealand aut Pattemore Philip K. Department of Paediatrics, Christchurch Hospital Christchurch, New Zealand aut Grimwood Keith Department of Paediatrics, University of Melbourne Parkville, Victoria, Australia 3052 aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/6(1996-06), 1155-1164 0305-7453 37:6<1155 1996 37 jac https://doi.org/10.1093/jac/37.6.1155 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.6.1155 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Barclay Murray L. Department of Clinical Pharmacology, Christchurch Hospital Christchurch, New Zealand aut NATIONALLICENCE 700 1- Begg Evan J. Department of Clinical Pharmacology, Christchurch Hospital Christchurch, New Zealand aut NATIONALLICENCE 700 1- Chambers Stephen T. Department of Infectious Diseases, Christchurch Hospital Christchurch, New Zealand aut NATIONALLICENCE 700 1- Thornley Peter E. Department of Respiratory, Christchurch Hospital Christchurch, New Zealand aut NATIONALLICENCE 700 1- Pattemore Philip K. Department of Paediatrics, Christchurch Hospital Christchurch, New Zealand aut NATIONALLICENCE 700 1- Grimwood Keith Department of Paediatrics, University of Melbourne Parkville, Victoria, Australia 3052 aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/6(1996-06), 1155-1164 0305-7453 37:6<1155 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford